1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2.
Research Methodology
2.1.
Objective of
the Study
2.2.
Baseline
Methodology
2.3.
Key Industry
Partners
2.4.
Major
Association and Secondary Sources
2.5.
Forecasting
Methodology
2.6.
Data
Triangulation & Validation
2.7.
Assumptions
and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
5. Global
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
5.1.
Market Size & Forecast
5.1.1. By Value
5.2.
Market Share & Forecast
5.2.1.
By Drug Class (Oxazolidinones, Lipopeptides,
Cephalosporin, Tetracycline, Folate Antagonist, Other)
5.2.2.
By Route of Administration (Oral Administration and
Parenteral Administration)
5.2.3.
By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies)
5.2.4.
By Region
5.2.5. By Company (2023)
5.3.
Market Map
5.3.1. By Drug Class
5.3.2. By Route of
Administration
5.3.3. By Distribution
Channel
5.3.4. By Region
6. Asia Pacific
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Route of
Administration
6.2.3. By Distribution
Channel
6.2.4. By Country
6.3.
Asia Pacific: Country Analysis
6.3.1. China
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Drug Class
6.3.1.2.2.
By Route of Administration
6.3.1.2.3.
By Distribution Channel
6.3.2. India
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Drug Class
6.3.2.2.2.
By Route of Administration
6.3.2.2.3.
By Distribution Channel
6.3.3. Australia
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Drug Class
6.3.3.2.2.
By Route of Administration
6.3.3.2.3.
By Distribution Channel
6.3.4. Japan
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Drug Class
6.3.4.2.2.
By Route of Administration
6.3.4.2.3.
By Distribution Channel
6.3.5. South Korea
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Drug Class
6.3.5.2.2.
By Route of Administration
6.3.5.2.3.
By Distribution Channel
7. Europe
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of
Administration
7.2.3. By
Distribution Channel
7.2.4. By
Country
7.3.
Europe: Country Analysis
7.3.1. France
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Drug Class
7.3.1.2.2.
By Route of Administration
7.3.1.2.3.
By Distribution Channel
7.3.2. Germany
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Drug Class
7.3.2.2.2.
By Route of Administration
7.3.2.2.3.
By Distribution Channel
7.3.3. Spain
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Drug Class
7.3.3.2.2.
By Route of Administration
7.3.3.2.3.
By Distribution Channel
7.3.4. Italy
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Drug Class
7.3.4.2.2.
By Route of Administration
7.3.4.2.3.
By Distribution Channel
7.3.5. United Kingdom
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Drug Class
7.3.5.2.2.
By Route of Administration
7.3.5.2.3.
By Distribution Channel
8. North America
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of
Administration
8.2.3. By Distribution
Channel
8.2.4. By Country
8.3.
North America: Country Analysis
8.3.1. United States
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Drug Class
8.3.1.2.2.
By Route of Administration
8.3.1.2.3.
By Distribution Channel
8.3.2. Mexico
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Drug Class
8.3.2.2.2.
By Route of Administration
8.3.2.2.3.
By Distribution Channel
8.3.3. Canada
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Drug Class
8.3.3.2.2.
By Route of Administration
8.3.3.2.3.
By Distribution Channel
9. South America
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1.
By Drug Class
9.2.2.
By Route of Administration
9.2.3.
By Distribution Channel
9.2.4. By Country
9.3.
South America: Country Analysis
9.3.1. Brazil
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Drug Class
9.3.1.2.2.
By Route of Administration
9.3.1.2.3.
By Distribution Channel
9.3.2. Argentina
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Drug Class
9.3.2.2.2.
By Route of Administration
9.3.2.2.3.
By Distribution Channel
9.3.3. Colombia
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Drug Class
9.3.3.2.2.
By Route of Administration
9.3.3.2.3.
By Distribution Channel
10. Middle East and
Africa Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3.
By Distribution Channel
10.2.4. By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Drug Class
10.3.1.2.2.
By Route of Administration
10.3.1.2.3.
By Distribution Channel
10.3.2. Saudi Arabia
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Drug Class
10.3.2.2.2.
By Route of Administration
10.3.2.2.3.
By Distribution Channel
10.3.3. UAE
Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Drug Class
10.3.3.2.2.
By Route of Administration
10.3.3.2.3.
By Distribution Channel
10.3.4. Egypt Methicillin-resistant
Staphylococcus Aureus Drugs Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1.
By Drug Class
10.3.4.2.2.
By Route of Administration
10.3.4.2.3.
By Distribution Channel
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers & Acquisitions
13.
Global Methicillin-resistant Staphylococcus Aureus Drugs
Market: SWOT Analysis
14. Porter’s Five Forces
Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Product
15.
Competitive Landscape
15.1. Melinta Therapeutics LLC
15.1.1.
Business Overview
15.1.2.
Company Snapshot
15.1.3.
Financials (If Listed)
15.1.4.
Product & Service Offerings
15.1.5.
Recent Developments
15.1.6.
Key Personnel
15.1.7.
SWOT Analysis
15.2. Basilea Pharmaceutica Ltd.
15.3. Theravance Biopharma
15.4. Wockhardt Limited
15.5. Paratek Pharmaceuticals, Inc.
15.6. Seres Therapeutics Inc.
15.7. Merck & Co. Inc.
15.8. AbbVie Inc
16. Strategic Recommendations
17. About Us & Disclaimer